EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

Bryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, Mark B Leick iD, Christopher W Mount, Leonora Balaj, Sarah Nikiforow, Bob S Carter iD, William T Curry, Kathleen Gallagher, Marcela V Maus iD

New England Journal of Medicine · 11.04.2024 · 390 (14) · 1290-1298

DOI: 10.1056/nejmoa2314390 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 11.04.2024. Verfasst von Bryan D Choi und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Cellular Immunotherapy Program (B.D.C., M.J.F., M.B.L., C.W.M., K.G., M.V.M.) and Krantz Family Center for Cancer Research (M.B.L., K.G., M.…. Hauptthemen laut MEDLINE: ErbB Receptors, Glioblastoma, Immunotherapy, Adoptive, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 491-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Gateway for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsGlioblastomaImmunotherapy, AdoptiveReceptors, Antigen, T-CellReceptors, Chimeric AntigenHumansCD8-Positive T-LymphocytesNeoplasm Recurrence, Local

Substanzen

ErbB ReceptorsReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • From the Cellular Immunotherapy Program (B.D.C., M.J.F., M.B.L., C.W.M., K.G., M.V.M.) and Krantz Family Center for Cancer Research (M.B.L., K.G., M.V.M.), Mass General Cancer Center, and the Departments of Neurology (E…

ORCID-Profile: Mark B Leick, Bob S Carter, Marcela V Maus

Förderung

  • NCI NIH HHS
  • Gateway for Cancer Research

Zitieren

APA

Choi, B. D., Gerstner, E. R., Frigault, M. J., Leick, M. B., Mount, C. W., Balaj, L., Nikiforow, S., Carter, B. S., Curry, W. T., Gallagher, K., & Maus, M. V. (2024). Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. New England Journal of Medicine, 390(14), 1290-1298. https://doi.org/10.1056/nejmoa2314390

Vancouver

Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. New England Journal of Medicine. 2024;390(14):1290-1298. doi:10.1056/nejmoa2314390

BibTeX
@article{Choi2024,
  author = {Choi, Bryan D and Gerstner, Elizabeth R and Frigault, Matthew J and Leick, Mark B and Mount, Christopher W and Balaj, Leonora and Nikiforow, Sarah and Carter, Bob S and Curry, William T and Gallagher, Kathleen and Maus, Marcela V},
  title = {Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {14},
  pages = {1290--1298},
  doi = {10.1056/nejmoa2314390}
}
Kostenlos starten →